
NASDAQ:SBRA
This summary was created by AI, based on 1 opinions in the last 12 months.
Sabra Health Care REIT (SBRA-Q) is emerging as a compelling investment choice, particularly for 2026, owing to its strategic positioning in the nursing and behavioral health spaces. The stock is currently trading at 12 times its funds from operations (FFO), which is notably lower than the broader market average, making it seem attractive from a valuation perspective. With a substantial dividend yield of 6.5%, it appeals to income-focused investors while also benefiting from positive demographic trends. Analysts project a 5.5% growth in earnings for this year, coupled with a 17% increase in the previous year, reflecting strong momentum in its operational fundamentals. Additionally, Sabra is perceived to be resilient against potential threats from AI, with some experts even suggesting it could leverage AI advancements to enhance its service delivery and efficiency.
Sabra Health Care REIT is a American stock, trading under the symbol SBRA (previously SBRA-Q on Stockchase) on the NASDAQ (SBRA). It is usually referred to as NASDAQ:SBRA or SBRA
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on SBRA (previously SBRA-Q on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is STRONG BUY. Read the latest stock experts' ratings for Sabra Health Care REIT.
Sabra Health Care REIT was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Sabra Health Care REIT.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Sabra Health Care REIT.
Sabra Health Care REIT is followed by 6 investors on Stockchase and is a trending stock that is worth watching.
On 2026-08-14, Sabra Health Care REIT (SBRA) stock closed at a price of $20.32.
Her top pick of 2026. Trades at 12x FFO, half the market's, and pays a 6.5% dividend. They are in the nursing space (retirement and skilled), and behavioural health. Enjoys demographic winds. Earnings to grow 5.5% this year. Up 17% last year, so has momentum as well as fundamentals. Is not threatened by AI, and could even benefit Sabra.